SLC HEALTH STRATEGIES, LLC for NOVO NORDISK PHARMACEUTICALS, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015 S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening Human growth hormone, obesity and rare disease matters HR 3742, Access to Marketplace Insurance Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Medicare/Medicaid MMM
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015 PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015 S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications HR 6 - 21st Century Cures Act In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Budget/Appropriations BUD
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113 HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Pharmacy PHA
HR 6 - 21st Century Cures Act FDA issues regarding biosimilar products; 340B program matters
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.